Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

Victor A. Levin, Luc Bidaut, Ping Hou, Ashok J. Kumar, Jeffrey S. Wefel, B. Nebiyou Bekele, Sujit Prabhu, Monica Loghin, Mark R. Gilbert, Edward F. Jackson

    Research output: Contribution to journalArticle

    320 Citations (Scopus)

    Abstract

    Purpose: To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain.

    Methods and Materials: A total of 14 patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system radiation necrosis. All patients were required to have radiographic or biopsy proof of central nervous system radiation necrosis and progressive neurologic symptoms or signs. Eligible patients had undergone irradiation for head-and-neck carcinoma, meningioma, or low- to mid-grade glioma. Patients were randomized to receive intravenous saline or bevacizumab at 3-week intervals. The magnetic resonance imaging findings 3 weeks after the second treatment and clinical signs and symptoms defined the response or progression.

    Results: The volumes of necrosis estimated on T-2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced magnetic resonance imaging scans demonstrated that although no patient receiving placebo responded (0 of 7), all bevacizumab-treated patients did so (5 of 5 randomized and 7 of 7 crossover) with decreases in T2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced volumes and a decrease in endothelial transfer constant. All bevacizumab-treated patients and none of the placebo-treated patients showed improvement in neurologic symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all four study doses, only 2 patients had experienced a recurrence of magnetic resonance imaging changes consistent with progressive radiation necrosis; one patient received a single additional dose of beyacizumab and the other patient received two doses.

    Conclusion: The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer. (c) 2011 Elsevier Inc.

    Original languageEnglish
    Pages (from-to)1487-1495
    Number of pages9
    JournalInternational Journal of Radiation Oncology, Biology, Physics
    Volume79
    Issue number5
    Early online date16 Apr 2010
    DOIs
    Publication statusPublished - 1 Apr 2011

    Keywords

    • Brain edema
    • Magnetic resonance imaging
    • Volumetric magnetic resonance imaging changes
    • Endothelial transfer constant
    • K-trans
    • Neurotoxicity
    • Vascular permeability factor
    • Endothelial growth factor
    • Cord barrier breakdown
    • Up regulation
    • Tumor
    • Brain
    • Radiotherapy
    • VEGF

    Cite this

    Levin, Victor A. ; Bidaut, Luc ; Hou, Ping ; Kumar, Ashok J. ; Wefel, Jeffrey S. ; Bekele, B. Nebiyou ; Prabhu, Sujit ; Loghin, Monica ; Gilbert, Mark R. ; Jackson, Edward F. / Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. In: International Journal of Radiation Oncology, Biology, Physics. 2011 ; Vol. 79, No. 5. pp. 1487-1495.
    @article{cd2c1871be5643d89948d54979ba7d3d,
    title = "Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system",
    abstract = "Purpose: To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain.Methods and Materials: A total of 14 patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system radiation necrosis. All patients were required to have radiographic or biopsy proof of central nervous system radiation necrosis and progressive neurologic symptoms or signs. Eligible patients had undergone irradiation for head-and-neck carcinoma, meningioma, or low- to mid-grade glioma. Patients were randomized to receive intravenous saline or bevacizumab at 3-week intervals. The magnetic resonance imaging findings 3 weeks after the second treatment and clinical signs and symptoms defined the response or progression.Results: The volumes of necrosis estimated on T-2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced magnetic resonance imaging scans demonstrated that although no patient receiving placebo responded (0 of 7), all bevacizumab-treated patients did so (5 of 5 randomized and 7 of 7 crossover) with decreases in T2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced volumes and a decrease in endothelial transfer constant. All bevacizumab-treated patients and none of the placebo-treated patients showed improvement in neurologic symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all four study doses, only 2 patients had experienced a recurrence of magnetic resonance imaging changes consistent with progressive radiation necrosis; one patient received a single additional dose of beyacizumab and the other patient received two doses.Conclusion: The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer. (c) 2011 Elsevier Inc.",
    keywords = "Brain edema, Magnetic resonance imaging, Volumetric magnetic resonance imaging changes, Endothelial transfer constant, K-trans, Neurotoxicity, Vascular permeability factor, Endothelial growth factor, Cord barrier breakdown, Up regulation, Tumor, Brain, Radiotherapy, VEGF",
    author = "Levin, {Victor A.} and Luc Bidaut and Ping Hou and Kumar, {Ashok J.} and Wefel, {Jeffrey S.} and Bekele, {B. Nebiyou} and Sujit Prabhu and Monica Loghin and Gilbert, {Mark R.} and Jackson, {Edward F.}",
    year = "2011",
    month = "4",
    day = "1",
    doi = "10.1016/j.ijrobp.2009.12.061",
    language = "English",
    volume = "79",
    pages = "1487--1495",
    journal = "International Journal of Radiation Oncology, Biology, Physics",
    issn = "0360-3016",
    publisher = "Elsevier",
    number = "5",

    }

    Levin, VA, Bidaut, L, Hou, P, Kumar, AJ, Wefel, JS, Bekele, BN, Prabhu, S, Loghin, M, Gilbert, MR & Jackson, EF 2011, 'Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system', International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 5, pp. 1487-1495. https://doi.org/10.1016/j.ijrobp.2009.12.061

    Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. / Levin, Victor A.; Bidaut, Luc; Hou, Ping; Kumar, Ashok J.; Wefel, Jeffrey S.; Bekele, B. Nebiyou; Prabhu, Sujit; Loghin, Monica; Gilbert, Mark R.; Jackson, Edward F.

    In: International Journal of Radiation Oncology, Biology, Physics, Vol. 79, No. 5, 01.04.2011, p. 1487-1495.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

    AU - Levin, Victor A.

    AU - Bidaut, Luc

    AU - Hou, Ping

    AU - Kumar, Ashok J.

    AU - Wefel, Jeffrey S.

    AU - Bekele, B. Nebiyou

    AU - Prabhu, Sujit

    AU - Loghin, Monica

    AU - Gilbert, Mark R.

    AU - Jackson, Edward F.

    PY - 2011/4/1

    Y1 - 2011/4/1

    N2 - Purpose: To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain.Methods and Materials: A total of 14 patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system radiation necrosis. All patients were required to have radiographic or biopsy proof of central nervous system radiation necrosis and progressive neurologic symptoms or signs. Eligible patients had undergone irradiation for head-and-neck carcinoma, meningioma, or low- to mid-grade glioma. Patients were randomized to receive intravenous saline or bevacizumab at 3-week intervals. The magnetic resonance imaging findings 3 weeks after the second treatment and clinical signs and symptoms defined the response or progression.Results: The volumes of necrosis estimated on T-2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced magnetic resonance imaging scans demonstrated that although no patient receiving placebo responded (0 of 7), all bevacizumab-treated patients did so (5 of 5 randomized and 7 of 7 crossover) with decreases in T2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced volumes and a decrease in endothelial transfer constant. All bevacizumab-treated patients and none of the placebo-treated patients showed improvement in neurologic symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all four study doses, only 2 patients had experienced a recurrence of magnetic resonance imaging changes consistent with progressive radiation necrosis; one patient received a single additional dose of beyacizumab and the other patient received two doses.Conclusion: The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer. (c) 2011 Elsevier Inc.

    AB - Purpose: To conduct a controlled trial of bevacizumab for the treatment of symptomatic radiation necrosis of the brain.Methods and Materials: A total of 14 patients were entered into a placebo-controlled randomized double-blind study of bevacizumab for the treatment of central nervous system radiation necrosis. All patients were required to have radiographic or biopsy proof of central nervous system radiation necrosis and progressive neurologic symptoms or signs. Eligible patients had undergone irradiation for head-and-neck carcinoma, meningioma, or low- to mid-grade glioma. Patients were randomized to receive intravenous saline or bevacizumab at 3-week intervals. The magnetic resonance imaging findings 3 weeks after the second treatment and clinical signs and symptoms defined the response or progression.Results: The volumes of necrosis estimated on T-2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced magnetic resonance imaging scans demonstrated that although no patient receiving placebo responded (0 of 7), all bevacizumab-treated patients did so (5 of 5 randomized and 7 of 7 crossover) with decreases in T2-weighted fluid-attenuated inversion recovery and T-1-weighted gadolinium-enhanced volumes and a decrease in endothelial transfer constant. All bevacizumab-treated patients and none of the placebo-treated patients showed improvement in neurologic symptoms or signs. At a median of 10 months after the last dose of bevacizumab in patients receiving all four study doses, only 2 patients had experienced a recurrence of magnetic resonance imaging changes consistent with progressive radiation necrosis; one patient received a single additional dose of beyacizumab and the other patient received two doses.Conclusion: The Class I evidence of bevacizumab efficacy from the present study in the treatment of central nervous system radiation necrosis justifies consideration of this treatment option for people with radiation necrosis secondary to the treatment of head-and-neck cancer and brain cancer. (c) 2011 Elsevier Inc.

    KW - Brain edema

    KW - Magnetic resonance imaging

    KW - Volumetric magnetic resonance imaging changes

    KW - Endothelial transfer constant

    KW - K-trans

    KW - Neurotoxicity

    KW - Vascular permeability factor

    KW - Endothelial growth factor

    KW - Cord barrier breakdown

    KW - Up regulation

    KW - Tumor

    KW - Brain

    KW - Radiotherapy

    KW - VEGF

    U2 - 10.1016/j.ijrobp.2009.12.061

    DO - 10.1016/j.ijrobp.2009.12.061

    M3 - Article

    VL - 79

    SP - 1487

    EP - 1495

    JO - International Journal of Radiation Oncology, Biology, Physics

    JF - International Journal of Radiation Oncology, Biology, Physics

    SN - 0360-3016

    IS - 5

    ER -